Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in Myelofibrosis
NCT05835466Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of reparixin in myelofibrosis (MF), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Efficacy of reparixin treatment per IWG/ELN criteria at 24 weeks. Started Jul 2023; status: recruiting.
02
Drugs
reparixin
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05835466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835466.